If you follow developments in weight-management research, you may have started seeing the word retatrutide sometimes shortened online to “Reta”.
Interest has increased following the publication of clinical trial results, but there is an important distinction to make from the outset:
Retatrutide is an investigational medicine. It is not currently authorised for public use in the UK or elsewhere.
It should therefore not be viewed as a treatment that people can currently purchase or request from a UK weight-management provider.
Eli Lilly, the company developing retatrutide, states that it is currently available only through its clinical trials while its safety and effectiveness continue to be evaluated.
What is retatrutide?
Retatrutide is an investigational medicine being developed by Eli Lilly.
It is known scientifically as a triple hormone receptor agonist because it activates three different receptors:
GIP
GLP-1
Glucagon
These receptors are involved in several processes within the body, including appetite regulation, glucose metabolism and energy balance.
Retatrutide is currently being investigated as a once-weekly subcutaneous injection in clinical trials.
You may have seen retatrutide referred to online as a “GLP-3”. This is not a recognised scientific category. Lilly states that the more accurate description is a triple agonist because the medicine acts on three separate receptors.
Why is there so much interest in retatrutide?
Much of the recent interest has followed results from the Phase 3 TRIUMPH-1 clinical trial.
The trial included adults with obesity, or overweight alongside at least one weight-related health condition, who did not have diabetes.
In results announced in May 2026, participants receiving the highest studied dose experienced an average body-weight reduction of 28.3% at 80 weeks under the study's efficacy analysis.
A subgroup of participants with a starting BMI of 35 or above who continued into an extension experienced an average reduction of 30.3% at 104 weeks at the highest studied dose.
These figures have understandably attracted attention, but they need to be interpreted carefully.
They are averages from a controlled clinical trial. They do not mean that everybody would experience the same result, and retatrutide's overall benefits and risks are still being evaluated.
Is retatrutide approved in the UK?
No.
As of September 2026, retatrutide has not received regulatory approval for public use.
Eli Lilly states that retatrutide has not been approved by any medicines regulator and is legally available only to participants in its clinical trials.
There is therefore no legitimate retail version of retatrutide available to UK consumers at present.
Can you buy retatrutide online?
This is an especially important safety issue.
Products claiming to contain retatrutide are being advertised online and through social media, but this does not mean they are genuine clinical-trial retatrutide.
Lilly has warned that products claiming to be retatrutide outside its authorised clinical trials may contain unknown ingredients, impurities, incorrect quantities of active ingredient or completely different substances.
The UK MHRA has also warned against unauthorised weight-management medicines and against businesses promoting medicines that do not yet hold a marketing authorisation.
Consumers should not purchase or inject substances marketed as “research retatrutide”, “Reta” or similar products from unregulated online sellers.
What have clinical trials shown so far?
Retatrutide is being studied in a large Phase 3 programme.
Research areas include obesity, type 2 diabetes and several obesity-related health conditions.
In the TRIUMPH-1 Phase 3 study, the reported average body-weight changes at 80 weeks under the efficacy analysis were:
19.0% with the 4 mg study dose
25.9% with the 9 mg study dose
28.3% with the 12 mg study dose
2.2% with placebo
These results came from a randomised, double-blind, placebo-controlled clinical trial and should not be interpreted as a promise or prediction of individual weight loss.
Further trials are continuing to evaluate both efficacy and safety across different groups of participants.
What side effects have been reported in the research?
In TRIUMPH-1, the most commonly reported adverse events in participants receiving retatrutide included:
Nausea
Diarrhoea
Constipation
Vomiting
Other adverse events were also reported.
The frequency of some gastrointestinal effects increased at higher study doses. Some participants discontinued treatment because of adverse events.
These findings are another reason why experimental medicines should not be self-sourced or used without appropriate clinical and regulatory oversight.
The complete safety profile of retatrutide is still being established.
When will retatrutide become available in the UK?
There is currently no confirmed UK availability date.
Before a medicine can be routinely supplied to patients, its clinical development programme must progress through the necessary regulatory review process.
Regulators examine evidence relating to quality, safety and efficacy before determining whether a medicine can be authorised.
Until that process has taken place, claims that retatrutide is “available now” in the UK should be treated with considerable caution.
What should people interested in weight management do now?
Medical weight management should always begin with an individual assessment rather than choosing a medicine based on social-media trends or headline trial results.
There are a number of factors that healthcare professionals may need to consider, including medical history, BMI, existing conditions, current medication and an individual's wider health goals.
To see if you are eligible for existing weight loss medicaiton, complete our consultation.
At Shape⁸, our approach is centred around clinical assessment, personalised weight-management support and ongoing care.
We do not supply or promote unlicensed retatrutide.
Mandy's Thoughts
There is always enormous interest when a new potential weight-management medicine appears in the news, particularly when early research receives a lot of attention online.
What I think is really important is separating genuine medical research from what we see being sold or promoted on social media.
Retatrutide is interesting from a research perspective, but right now it remains an investigational medicine.
My advice is always to use properly regulated healthcare providers, have an appropriate clinical assessment and never be tempted to buy an experimental product simply because it is trending online.
Frequently Asked Questions
What is Reta?
“Reta” is an informal abbreviation sometimes used online for retatrutide. It is not a separate medicine.
Is retatrutide available in the UK?
No. Retatrutide remains investigational and is not currently authorised for public use.
Is retatrutide an injection?
In clinical trials, retatrutide is being studied as a once-weekly subcutaneous injection.
Is retatrutide a GLP-1 medicine?
Retatrutide activates the GLP-1 receptor, but it also activates GIP and glucagon receptors. It is therefore described as a triple hormone receptor agonist.
Can I join a Shape⁸ retatrutide waiting list?
No. Shape⁸ does not operate a waiting list for retatrutide. It is an investigational medicine and is not currently authorised for public use.
Is retatrutide safe?
Its safety and efficacy are still being evaluated in clinical trials. It has not yet completed the regulatory approval process.
Conclusion
Retatrutide is an important area of ongoing research, and the clinical trial programme will continue to provide more information about its potential benefits and risks.
For now, however, the key message for UK consumers is simple:
Retatrutide is still investigational and is not currently an authorised treatment available to the public.
Anyone considering medical support for their weight should seek advice from an appropriately regulated healthcare professional rather than purchasing medicines or experimental substances from unregulated sources.
Important Information
This article is provided for general educational purposes only and does not constitute medical advice or the promotion of retatrutide.
Retatrutide is an investigational medicine and is not currently authorised for public use in the UK.
Never purchase or use medicines or substances from unregulated sources. Individual medical advice should always be obtained from an appropriately qualified healthcare professional.
Sources
MHRA — UK guidance and warnings concerning the promotion of unlicensed and prescription-only weight-management medicines.
